摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(7-(2-tetrahydropyranyloxy)-3(Z)-hepten-1,5-diynyl)benzonitrile

中文名称
——
中文别名
——
英文名称
2-(7-(2-tetrahydropyranyloxy)-3(Z)-hepten-1,5-diynyl)benzonitrile
英文别名
2-(7-(tetrahydropyranyloxy)-3-(Z)-hepten-1,5-diynyl)-benzonitrile;2-[(Z)-7-(oxan-2-yloxy)hept-3-en-1,5-diynyl]benzonitrile
2-(7-(2-tetrahydropyranyloxy)-3(Z)-hepten-1,5-diynyl)benzonitrile化学式
CAS
——
化学式
C19H17NO2
mdl
——
分子量
291.349
InChiKey
FHNFIYJZXHGKDR-UPHRSURJSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    22
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.32
  • 拓扑面积:
    42.2
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    2-(7-(2-tetrahydropyranyloxy)-3(Z)-hepten-1,5-diynyl)benzonitrilesodium methylate二甲基亚砜 作用下, 以 甲醇 为溶剂, 反应 6.0h, 以21%的产率得到1-(Tetrahydro-pyran-2-yloxymethyl)-5H-phenanthridin-6-one
    参考文献:
    名称:
    Anionic Cycloaromatization of 1-Aryl-3-hexen-1,5-diynes Initiated by Methoxide Addition:  Synthesis of Phenanthridinones, Benzo[c]phenanthridinones, and Biaryls
    摘要:
    Treatment of 2-((Z)-6-substituted-3-hexene-1,5-diynyl)benzonitriles with sodium methoxide in refluxing methanol in the presence of a polar aprotic solvent, such as DMSO, HMPA, THF, or 18-crown-6, gave phenanthridinones in 21-77% yields. In these cases, addition of 10% DMSO into the reaction mixture gave the highest yield. On the other hand, methanolysis of 2-(2-(2-dalkynylphenyl)ethynyl)benzonitriles under the same reaction conditions gave benzo[c]phenanthridinones in 31-57% yields. Methanolysis of (Z)-1-aryl-3-hexen-1,5-diynes in the presence of 2 equiv of tetrabutylammonium iodide gave biaryls in 14-64% yields. It is found that the reactions with aryl groups bearing electron-withdrawing groups proceeded at greater rates and gave better yields.
    DOI:
    10.1021/jo010693h
  • 作为产物:
    参考文献:
    名称:
    Pharmaceutical compositions comprising aryl-substituted acyclic enediyne compounds
    摘要:
    一种药物组合物包括化合物的结构式(I):或其药用可接受的盐:其中R1=R2=H;或R1和R2一起形成由结构式表示的基团R3代表具有4-30个碳原子的取代或未取代的烷基,或具有3-30个碳原子的取代或未取代的芳基;和R4代表具有3-30个碳原子的取代或未取代的芳基;但R3不是丁基、戊基、四氢吡喃氧甲基、四氢吡喃氧丙基或苯基,当R1=R2=H和R4是邻氰基苯基时;且R3不是丁基,当R1=R2=H和R4是苯基时。该药物组合物可用于通过抑制拓扑异构酶I活性或阻断肿瘤/癌细胞的S期或G2/M期治疗患有肿瘤/癌症的受试者。
    公开号:
    US20050004211A1
点击查看最新优质反应信息

文献信息

  • Aryl-substituted acyclic enediyne compounds
    申请人:Wu Ming-Jung
    公开号:US20050004212A1
    公开(公告)日:2005-01-06
    This invention provides aryl-substituted acyclic enediyne compounds of formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 ═R 2 ═H; or R 1 and R 2 together form a moiety represented by the formula R 3 represents a substituted or unsubstituted alkyl having 4-30 carbon atoms, or a substituted or unsubstituted aryl group having 3-30 carbon atoms; and  R represents a substituted or unsubstituted aryl group having 3-30 carbon atoms; with the proviso that R 3 is not butyl, pentyl, tetrahydropyranyloxymethyl, tetrahydropyranyloxypropyl or phenyl when R 1 ═R 2 ═H and R 4 is o-cyanophenyl,; and with the proviso that R 3 is not butyl when R 1 ═R 2 ═H and R 4 is phenyl. The compounds of formula (I) are found to have inhibitory activities against topoisomerase I or act as a S phase or G2/M phase blocker.
    本发明提供了式(I)的芳基取代的无环炔二化合物或其药学上可接受的盐或溶剂,其中R1═R2═H;或R1和R2结合形成由式表示的基团R3,其中R3代表具有4-30个原子的取代或未取代的烷基,或具有3-30个原子的取代或未取代的芳基基团;而R代表具有3-30个原子的取代或未取代的芳基基团;但是当R1═R2═H且R4为o-基时,R3不是丁基,戊基,四氢吡喃甲基四氢吡喃丙基或基;而当R1═R2═H且R4为基时,R3不是丁基。发现式(I)的化合物具有抑制拓扑异构酶I的活性或作为S期或G2/M期阻滞剂的活性。
  • A Series of Enediynes as Novel Inhibitors of Topoisomerase I
    作者:Chi-Fong Lin、Pei-Chen Hsieh、Wen-Der Lu、Huey-Fen Chiu、Ming-Jung Wu
    DOI:10.1016/s0968-0896(01)00081-5
    日期:2001.7
    A series of acyclic enediynes, 2-((6-substituted)-3-hexen- 1,5-diynyl)benzonitriles (8-11), display potent inhibition against topoisomerase I without the formation of active biradical intermediates and show inhibitory activity against topoisomerase I at 10 muM, which is five times that of camptothecin from the results of agarose gel electrophoresis. (C) 2001 Elsevier Science Ltd. All rights reserved.
  • US7332623B2
    申请人:——
    公开号:US7332623B2
    公开(公告)日:2008-02-19
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫